Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Prognostic Value of 18F-FDG-PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

Research output: Contribution to journalReviewResearchpeer-review

  1. Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MRI of the Entire Spinal Cord-Worth the While or Waste of Time? A Retrospective Study of 74 Patients with Multiple Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Optimal Insertion Depth for Nasal Mid-Turbinate and Nasopharyngeal Swabs

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Listeria Monocytogenes Brain Abscesses in a Patient with Disseminated Non-Small Cellular Lung Cancer: MRI Findings

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Many studies have suggested a prognostic value of one or several positron emission tomography (PET) parameters in patients with small cell lung cancer (SCLC). However, studies are often small, and there is a considerable interstudy disagreement about which PET parameters have a prognostic value. The objective of this study was to perform a review and meta-analysis to identify the most promising PET parameter for prognostication. PubMed®, Cochrane, and Embase® were searched for papers addressing the prognostic value of any PET parameter at any treatment phase with any endpoint in patients with SCLC. Pooled hazard ratios (HRs) were calculated by a random effects model for the prognostic value of the baseline maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV). The qualitative analysis included 38 studies, of these, 19 studies were included in the meta-analyses. The pooled results showed that high baseline MTV was prognostic for overall survival (OS) (HR: 2.83 (95% confidence interval [CI]: 2.00-4.01) and progression-free survival (PFS) (HR: 3.11 (95% CI: 1.99-4.90)). The prognostic value of SUVmax was less pronounced (OS: HR: 1.50 (95% CI: 1.17-1.91); PFS: HR: 1.24 (95% CI: 0.94-1.63)). Baseline MTV is a strong prognosticator for OS and PFS in patients with SCLC. MTV has a prognostic value superior to those of other PET parameters, but whether MTV is superior to other prognosticators of tumor burden needs further investigation.

Original languageEnglish
JournalDiagnostics
Volume11
Issue number2
ISSN2075-4418
DOIs
Publication statusPublished - Feb 2021

    Research areas

  • FDG-PET/CT, small cell lung cancer, prognosis, SUVmax, metabolic tumor volume

ID: 64232249